Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


CNS Pharmaceuticals, Inc. (CNSP) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/19/2021 8-K Quarterly results
06/07/2021 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/27/2021 PRE 14A Form PRE 14A - Other preliminary proxy statements:
05/18/2021 8-K Quarterly results
05/13/2021 10-Q Quarterly Report for the period ended March 31, 2021
04/30/2021 10-K/A Annual Report for the period ended December 31, 2020 [amend]
03/17/2021 8-K Quarterly results
02/25/2021 8-K Quarterly results
02/24/2021 GN WPD Pharmaceuticals Announces Berubicin Supply Agreement for the Upcoming Clinical Trials
02/18/2021 GN WPD and CNS Pharmaceuticals Announce Positive Opinion of the Polish Central Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 Study
02/16/2021 10-K/A Annual Report for the period ended December 31, 2020 [amend]
02/12/2021 8-K Quarterly results
02/12/2021 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/12/2021 10-K Annual Report for the period ended December 31, 2020
02/04/2021 EFFECT Form EFFECT - Notice of Effectiveness:
01/27/2021 S-3 Form S-3 - Registration statement under Securities Act of 1933:
01/07/2021 8-K Quarterly results
12/28/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement, with A.G.P./Alliance Global Partners, as representative of the several underwriters",
"Form of Warrant",
"Press release"
12/28/2020 GN CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application
12/23/2020 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
12/22/2020 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
12/21/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Portions of “Prospectus Summary” and “Risk Factors” section of CNS Pharmaceuticals, Inc.’ s Registration Statement on Form S-1 filed December 21, 2020"
12/21/2020 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
12/16/2020 GN InvestorBrandNetwork Announces ‘Want Money Got Money' Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco
12/11/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "CNS Pharmaceuticals, Inc. Investor Presentation – December 2020"
11/24/2020 GN CNS Pharmaceuticals Featured in Syndicated Broadcast Covering Recent Announcements for Glioblastoma Multiforme (GBM) Therapy
11/12/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "CNS Pharmaceuticals, Inc. Investor Presentation – November 2020"
11/12/2020 10-Q Quarterly Report for the period ended September 30, 2020
10/07/2020 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
10/07/2020 EFFECT Form EFFECT - Notice of Effectiveness:
09/25/2020 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
09/24/2020 GN CNS Pharmaceuticals and Image Analysis Group Partner to Further the Development of Berubicin
09/21/2020 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
Docs: "Purchase Agreement, by and between the Company and Lincoln Park Capital Fund, LLC",
"Registration Rights Agreement, by and between the Company and Lincoln Park Capital Fund, LLC"
09/16/2020 8-K/A Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "CNS Pharmaceuticals, Inc. Investor Presentation – September 2020"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy